Trends and uptake of new formulations of controlled-release oxycodone in Canada.

about

Trends and uptake of new formulations of controlled-release oxycodone in Canada.

Item

http://www.wikidata.org/entity/Q47717924

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Trends and uptake of new formulations of controlled-release oxycodone in Canada.

@en

Trends and uptake of new formulations of controlled-release oxycodone in Canada.

@nl

type

Item

label

Trends and uptake of new formulations of controlled-release oxycodone in Canada.

@en

Trends and uptake of new formulations of controlled-release oxycodone in Canada.

@nl

prefLabel

Trends and uptake of new formulations of controlled-release oxycodone in Canada.

@en

Trends and uptake of new formulations of controlled-release oxycodone in Canada.

@nl

P1476

Trends and uptake of new formulations of controlled-release oxycodone in Canada

@en

P2093

Canadian Network for Observational Drug Effect Studies (CNODES) Investigators

http://www.w3.org/2001/XMLSchema#string

J Michael Paterson

http://www.w3.org/2001/XMLSchema#string

Patricia Caetano

http://www.w3.org/2001/XMLSchema#string

Sonia Jain

http://www.w3.org/2001/XMLSchema#string

P2860

Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada

Trends in high-dose opioid prescribing in Canada

The burden of premature opioid-related mortality

Trends and changes in prescription opioid analgesic dispensing in Canada 2005-2012: an update with a focus on recent interventions

Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone.

Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.

FDA tightens indications for using long-acting and extended-release opioids to treat chronic pain.

The promotion and marketing of oxycontin: commercial triumph, public health tragedy.

P304

520-525

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PDS.4390

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David Henry

Ingrid Sketris

Tara Gomes

P577

2018-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29359446

http://www.w3.org/2001/XMLSchema#string

P932

5947657

http://www.w3.org/2001/XMLSchema#string